This protocol addresses patients with a confirmed diagnosis of indolent primary hepatic lymphoma (PHL). The relevant subtypes are marginal zone lymphoma (MZL), Grade 1–2 follicular lymphoma (FL), and low-grade B-cell lymphoma (BCL), NOS — all presenting as primary disease in the liver.
The primary clinical objective is achieving a complete response of the primary hepatic lymphoma.
For appropriate patients with indolent PHL, the management strategy incorporates a radiotherapy-based intervention directed at the liver, with response evaluation guiding further steps. The complete regimen details, eligibility criteria, sequencing, and response assessment parameters are available in the full structured protocol.
DOI: 10.3389/fonc.2025.1475118
Subgroup analysis was performed for diffuse large B-cell lymphoma (DLBCL) and indolent lymphomas, which included marginal zone lymphoma (MZL), Grade 1-2 follicular lymphoma (FL), and low-grade B-cell lymphoma (BCL), NOS.
Our results are encouraging for the use of RT for appropriate patients with indolent PHL, using the adaptive approach of 400 cGy in 1-2 fractions, with the option to receive an additional 20Gy based on PET-guided response assessment 3 months post-RT.